Literature DB >> 8610833

Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study.

D G Daniel1, T E Goldberg, D R Weinberger, J E Kleinman, D Pickar, L J Lubick, T S Williams.   

Abstract

OBJECTIVE: The purpose of this study was to compare the side effect +profiles of clozapine and risperidone.
METHOD: The subjects were 20 outpatients with schizophrenia or schizoaffective disorder who were clinically stable on a regimen of clozapine at the time of screening. They underwent a randomized-order crossover comparison of 6 weeks of risperidone treatment and 6 weeks of clozapine treatment. Clinical and neurocognitive variables were assessed by raters blind to medication status, and severity of side effects was determined from patients' self-reports.
RESULTS: Side effect measures, but not clinical ratings, were significantly different after 6 weeks of treatment with the two drugs. Patients required more benztropine for motor effects and complained of more insomnia with risperidone and more sedation with clozapine. Body weight was higher at the end of clozapine treatment than at the end of risperidone treatment.
CONCLUSIONS: In this exploratory study, the side effect profiles of clozapine and risperidone were consistent with the different pharmacodynamic profiles of the two drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8610833     DOI: 10.1176/ajp.153.3.417

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  14 in total

Review 1.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents.

Authors:  Frank Gianfrancesco; Michael B Durkin; Ramy Mahmoud; Ruey-Hua Wang
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  Functional dysconnectivity in schizophrenia associated with attentional modulation of motor function.

Authors:  Garry D Honey; Edith Pomarol-Clotet; Philip R Corlett; Rebekah A E Honey; Peter J McKenna; Edward T Bullmore; Paul C Fletcher
Journal:  Brain       Date:  2005-09-23       Impact factor: 13.501

Review 4.  Tolerability of atypical antipsychotics.

Authors:  C Stanniland; D Taylor
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

Review 5.  Conventional versus novel antipsychotics: changing concepts and clinical implications.

Authors:  G Remington; S A Chong
Journal:  J Psychiatry Neurosci       Date:  1999-11       Impact factor: 6.186

Review 6.  Risperidone. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

Review 7.  The use of atypical antipsychotics in the management of schizophrenia.

Authors:  M Campbell; P I Young; D N Bateman; J M Smith; S H Thomas
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

8.  Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms.

Authors:  Michael Riedel; Norbert Müller; Martin Strassnig; Ilja Spellmann; Rolf R Engel; Richard Musil; Sandra Dehning; Anette Douhet; Markus J Schwarz; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-11-04       Impact factor: 5.270

Review 9.  Adverse effects of atypical antipsychotics : differential risk and clinical implications.

Authors:  Peter M Haddad; Sonu G Sharma
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

10.  [Atypical antipsychotics in therapy refractory schizophrenia].

Authors:  I Schäfer; M Lambert; D Naber
Journal:  Nervenarzt       Date:  2004-01       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.